Covered recipient · General Payments record
NOMA A REHMAN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$3,125.63
- Reported across 193 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $583.34 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $377.30 | 23 |
| Genentech USA, Inc. | $75.14 | 4 |
| Lilly USA, LLC | $35.58 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $25.23 | 1 |
| EISAI INC. | $19.25 | 1 |
| Edwards Lifesciences Corporation | $19.20 | 1 |
| Averitas Pharma Inc. | $16.74 | 1 |
| Biogen, Inc. | $14.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.05 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933794 | CMS |
| ABBVIE INC. | $6.64 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933796 | CMS |
| ABBVIE INC. | $9.73 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933798 | CMS |
| ABBVIE INC. | $22.22 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933800 | CMS |
| ABBVIE INC. | $25.49 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933802 | CMS |
| ABBVIE INC. | $27.45 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933804 | CMS |
| ABBVIE INC. | $6.34 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933806 | CMS |
| ABBVIE INC. | $20.20 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933808 | CMS |
| ABBVIE INC. | $30.05 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933810 | CMS |
| ABBVIE INC. | $5.83 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933812 | CMS |
| ABBVIE INC. | $9.43 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933814 | CMS |
| ABBVIE INC. | $4.25 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933816 | CMS |
| ABBVIE INC. | $22.08 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933818 | CMS |
| ABBVIE INC. | $22.09 | 07/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933820 | CMS |
| ABBVIE INC. | $30.69 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933822 | CMS |
| ABBVIE INC. | $6.95 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933824 | CMS |
| ABBVIE INC. | $8.76 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933826 | CMS |
| ABBVIE INC. | $13.99 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933828 | CMS |
| ABBVIE INC. | $21.87 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933830 | CMS |
| ABBVIE INC. | $23.73 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933832 | CMS |
| ABBVIE INC. | $11.45 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933834 | CMS |
| ABBVIE INC. | $3.81 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933836 | CMS |
| ABBVIE INC. | $17.20 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105933838 | CMS |
| Averitas Pharma Inc. | $16.74 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133443243 | CMS |
| Biogen, Inc. | $14.90 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104808063 | CMS |
| Boston Scientific Corporation | $25.23 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092344962 | CMS |
| Edwards Lifesciences Corporation | $19.20 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138829788 | CMS |
| Eisai Inc. | $19.25 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110770677 | CMS |
| Genentech USA, Inc. | $14.29 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133082973 | CMS |
| Genentech USA, Inc. | $16.44 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133082981 | CMS |
| Genentech USA, Inc. | $16.47 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133082977 | CMS |
| Genentech USA, Inc. | $27.94 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133082969 | CMS |
| Lilly USA, LLC | $13.53 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135306153 | CMS |
| Lilly USA, LLC | $22.05 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135245197 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.